A comparative study of the capability
of MSCs isolated from different human
tissue sources to differentiate into
neuronal stem cells and dopaminergiclike cells
Nidaa A. Ababneh1 ,* , Ban Al-Kurdi1 ,* , Fatima Jamali1 and Abdalla Awidi1 ,2 ,3
1
Cell Therapy Center (CTC), the University of Jordan, Amman, Jordan
Hemostasis and Thrombosis Laboratory, School of Medicine, the University of Jordan, Amman, Jordan
3
Department of Hematology and Oncology, Jordan University Hospital, Amman, Jordan
*
These authors contributed equally to this work.
2
ABSTRACT
Submitted 27 October 2021
Accepted 3 February 2022
Published 17 March 2022
Corresponding author
Nidaa A. Ababneh,
nidaaanwar@gmail.com
Academic editor
Gwyn Gould
Additional Information and
Declarations can be found on
page 14
DOI 10.7717/peerj.13003
Copyright
2022 Ababneh et al.
Distributed under
Creative Commons CC-BY 4.0
Background. Neurodegenerative diseases are characterized by progressive neuronal loss
and degeneration. The regeneration of neurons is minimal and neurogenesis is limited
only to specific parts of the brain. Several clinical trials have been conducted using
Mesenchymal Stem Cells (MSCs) from different sources to establish their safety and
efficacy for the treatment of several neurological disorders such as Parkinson’s disease,
multiple sclerosis and amyotrophic lateral sclerosis.
Aim. The aim of this study was to provide a comparative view of the capabilities of
MSCs, isolated from different human tissue sources to differentiate into neuronal stem
cell-like cells (NSCs) and possibly into dopaminergic neural- like cells.
Methods. Mesenchymal stem cells were isolated from human bone marrow, adipose,
and Wharton’s jelly (WJ) tissue samples. Cells were characterized by flow cytometry for
their ability to express the most common MSC markers. The differentiation potential
was also assessed by differentiating them into osteogenic and adipogenic cell lineages.
To evaluate the capacity of these cells to differentiate towards the neural stem cell-like
lineage, cells were cultured in media containing small molecules. Cells were utilized for
gene expression and immunofluorescence analysis at different time points.
Results. Our results indicate that we have successfully isolated MSCs from bone
marrow, adipose tissue, and Wharton’s jelly. WJ-MSCs showed a slightly higher
proliferation rate after 72 hours compared to BM and AT derived MSCs. Gene
expression of early neural stem cell markers revealed that WJ-MSCs had higher
expression of Nestin and PAX6 compared to BM and AT-MSCs, in addition to LMX
expression as an early dopaminergic neural marker. Immunofluorescence analysis also
revealed that these cells successfully expressed SOX1, SOX2, Nestin, TUJ1, FOXA2 and
TH.
Conclusion. These results indicate that the protocol utilized has successfully differentiated BM, AT and WJ-MSCs into NSC-like cells. WJ-MSCs possess a higher potential to
transdifferentiate into NSC and dopaminergic-like cells. Thus, it might indicate that this
protocol can be used to induce MSC into neuronal lineage, which provides an additional
or alternative source of cells to be used in the neurological cell-based therapies.
OPEN ACCESS
How to cite this article Ababneh NA, Al-Kurdi B, Jamali F, Awidi A. 2022. A comparative study of the capability of MSCs
isolated from different human tissue sources to differentiate into neuronal stem cells and dopaminergic-like cells. PeerJ 10:e13003
http://doi.org/10.7717/peerj.13003
Subjects Biochemistry, Bioengineering, Cell Biology, Neuroscience
Keywords Mesenchymal stem cells, Differentiation, Neural stem cells, Dopaminergic neurons
INTRODUCTION
Mesenchymal stem cells (MSCs) are a population of cells characterized by their great
regenerative capacity and mutlipotent differentiation potential into multiple cell lineages
(Ullah, Subbarao & Rho, 2015). These cells can be easily isolated from different tissue
sources with minimal invasive procedures (Ullah, Subbarao & Rho, 2015). MSCs have
been isolated from adipose tissue, bone marrow, Wharton jelly, dental pulp and umbilical
cord blood. MSCs have the potential to differentiate into adipogenic, osteogenic and
chondrogenic lineages. Some studies have reported the ability of these cells to cross
lineage commitment and to differentiate into endodermal and ectodermal cell lineages
(Ullah, Subbarao & Rho, 2019; Orbay, Tobita & Mizuno, 2012; Ullah, Subbarao & Rho,
2015). Additionally, MSCs are hypoimmunogenic and have immunosuppressive properties.
All of these characteristics and the fact that MSCs are not burdened by ethical issues, vector
integration, genomic instability, inefficient generation and tumorigenic capacity associated
with embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), makes them
an attractive choice for tissues engineering and cell replacement therapies (Ullah, Subbarao
& Rho, 2019; Musiał-Wysocka, Kot & Majka, 2019; Wang, Yuan & Xie, 2018; Medvedev,
Shevchenko & Zakian, 2010).
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of
dopaminergic neurons, resulting in an impairment of the motor function (Alexander,
2004). The loss of these cells makes the PD an attractive model for cell replacement
therapies. No specific treatment is currently available to treat PD patients. Surgical
therapies as well as different pharmacological treatments have been utilized to relieve
some of the PD symptoms (Alexander, 2004; Dauer & Przedborski, 2003; Fu et al., 2015).
However, treatments usually fail after a while, due to the progressive nature of the disease.
Searching for a more effective therapeutic strategy is essential to hinder the progression of
dopaminergic neurons degeneration.
Several clinical trials have been conducted to assess the safety and efficacy of using
MSCs for the treatment of graft versus host disease, heart failure, bone and cartilage
diseases, neurodegenerative and spinal cord injuries (Musiał-Wysocka, Kot & Majka, 2019;
Ul Hassan, Hassan & Rasool, 2009; Ullah, Subbarao & Rho, 2015).
Different differentiation protocols have been utilized to direct MSCs towards the
neuronal lineage. Cell culture media supplemented with FGF2, EGF, BMP-9, retinoic acid,
and heparin have been used to induce MSCs derived from adipose tissue to cholinergic
and dopaminergic neuronal-like cells (Marei et al., 2018). Additionally, the soluble factors
sonic hedgehog (SHH), fibroblast growth factor 8 (FGF8), and basic fibroblast growth
factor (bFGF) along with final treatment with BDNF neurotrophic factor have been
successfully used to generate functional dopaminergic neurons from WJ, ASC, UC and
olfactory Mesenchymal Stem Cells (Boroujeni & Gardaneh, 2017; Khademizadeh et al.,
2019; Ul Hassan, Hassan & Rasool, 2009; Yang et al., 2013). Choroid Plexus Epithelial Cell,
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
2/18
Table 1 Summary of the different protocols utilized for Mesenchymal stem cell differentiation to
Dopaminergic neurons.
Protocol
Reference
Cell culture media supplemented with FGF2, EGF, BMP-9,
retinoic acid, and heparin
Marei et al. (2018)
choroid plexus epithelial cell-conditioned medium (CPECCM)
Boroujeni et al. (2017)
Cell culture media supplemented with sonic hedgehog
(SHH), 100 ng/mL fibroblast growth factors (FGF)-8 and
50 ng/mL bFGF
Khademizadeh et al. (2019)
Inducible lentivirus-mediated hGDNF gene in MSCs
Yang et al. (2013)
mesencephalic glial-cell, PA6 stromal cells-derived conditioned media have also been
used to induce dopaminergic differentiation on different stem cell types (Boroujeni et al.,
2017) Table 1. Transduction of MSCs with transcription factors required for dopaminergic
differentiation such as LMX1, NTN and GDNF using lentiviral or retroviral vectors have
been proved to be an efficient way to enhance the differentiation potential of MSCs towards
the dopaminergic lineage (Barzilay et al., 2009; Ul Hassan, Hassan & Rasool, 2009; Yang et
al., 2013) Table 1.
Most of the previous studies have shown variations in differentiation potential of
different types of MSCs into neuronal lineage. Hence, the aim of this study was to assess
and compare the neural dopaminergic differentiation capacity of MSCs isolated from
adipose tissue, bone marrow, and Whartons’ jelly. Such findings might assist in choosing
the appropriate cell source to be utilized in cell replacement and neural regenerative
therapies.
MATERIALS AND METHODS
Isolation and characterization of MSCs from different tissue sources
This study was conducted after obtaining an International Review Board (IRB/7/2019)
approval at the University of Jordan/Cell Therapy Center (CTC). Samples were collected
after all donors gave written informed consents.
Six samples from six different donors for each tissue type were used to isolate MSCs:
Adipose tissue (mean = 32.6 ± 5.4; three males and three females), Bone marrow (mean =
38.2 ± 7.0; three males and three females) and Wharton’s Jelly tissue (mean = 31.2 ± 3.5;
6 females). The isolation of stem cells was performed according to the protocols utilized
by following protocols, respectively (Bunnell et al., 2008; Gnecchi & Melo, 2009; Ranjbaran
et al., 2018). The isolated cells obtained from these tissues were cultured in Minimum
Essential Medium alpha (α-MEM; Gibco) supplemented with 5% pooled human platelet
lysate (hPL), 1% Antibiotic-Antimycotic (Gibco) and 1% Glutamax (Gibco). Cells at
70%–80% confluence were expanded until passages 1–3. Then cells were either used for
further experiments or stored in liquid nitrogen.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
3/18
Characterization of MSCs
Flow cytometry
Cells at passage 3 and 70% confluency were utilized for MSC surface markers assessment
using Human MSC Analysis Kit (BD, USA). Briefly, cells were detached with 1X TryplE
(Gibco) and washed twice with FACS buffer (PBS, 1% FBS). After that, cells were
resuspended in FACS buffer and the concentration was adjusted to 1 X 106 cells/ml.
Aliquots of 100 µl from the cell suspension were placed in test tubes and incubated for
30 min in the dark with fluorochrome conjugated antibodies against CD-44, CD-105,
CD-73, CD-90 and a negative cocktail mix according to the manufacturer instructions.
Cells were then centrifuged at 300xg for 5 min and resuspended in 500 µl FACS buffer.
Analysis was performed using FACSCantoTM (BD) and the data were analyzed using Diva
software.
Multilineage differentiation
Adipogenic differentiation was performed using StemPro Adipogenesis differentiation
media (Invitrogen, Waltham, MA, USA) for 14 days. Cells were washed twice with
PBS, fixed and stained with Oil red O stain to confirm the adipogenic differentiation
potential. StemPro Osteogenic differentiation kit (Invitrogen, USA) was used to induce
ASC differentiation towards the urothelial lineage. After 21 days in culture, cells were
washed, fixed and stained with Alizarin red stain to verify osteogenic differentiation. Cells
under normal culture conditions were used as a negative control.
Cell proliferation analysis
MSCs were seeded onto 96-well plates at a unified seeding density of 5,000 cells/well
and cultured under normal conditions for three days. MTT (3-(4, 5-dimethylthiazolyl2)2, 5-diphenyltetrazolium bromide (ATCC R 301010K) was used to measure the cell
proliferation rate after 24, 48 and 72 h according to the manufacturer’s instructions.
Neural induction
Cells were seeded on Matrigel coated six well plates and coverslips, and in the following
day medium was changed into neural induction media consisting of Dulbecco’s modified
Eagle’s medium F12 (DMEM/F12; Gibco) supplemented with 3% Knockout Serum
Replacement (KSR, Gibco), 1% Glutamax (Gibco, Waltham, MA, USA), 1% non-essential
amino acid (NEAA, Gibco), 4 ng/mL basic fibroblast growth factor (bFGF; Peprotech),
10 µM SB431542 (Sigma), and 0.5 µM LDN193289 (Sigma) for 8 days. Following, cells were
passaged at 1:3 split ratio and media was switched every other day as the following: Day 7
and 8 75% neural induction media and 25% of Neuroabasal media consisting of 0.5% B27,
0.5% N2, 100 nM LDN, 100 ng/mL SHH C24II, 2 µM Purmorphamine, 100 ng/mL FGF8a,
3 µM CHIR-99021. Day 9 and 10 50% neural induction media and 50% Neuroabasal
media 0.5% B27, 0.5% N2 100 nM LDN 3 µM CHIR-99021. Day 11 and 12 25% neural
induction media and 75% of Neuroabasal media 100 nM LDN 3 µM CHIR-99021. Day 13
onward 3 µM CHIR-99021, 10 ng/ µl BDNF, 10 ng/ µl GDNF, 1 ng/mL TGFb3, 10 µM
DAPT, 200 µM Ascorbic Acid and 500 µM db-cAMP.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
4/18
Table 2 qPCR Primer sequence.
Gene Name
Forward (5 →3)
Reverse (5 →3)
GAPDH
CCTGTTCGACAGTCAGCCG
CGACCAAATCCGTTGACTCC
NKX6.1
ATTCGTTGGGGATGACAGAG
CCGAGTCCTGCTTCTTCTTG
Nestin
AGAAACAGGGCCTACAGAGC
GAGGGAAGTCTTGGAGCCAC
Sox-2
TAGAGCTAGACTCCGGGCGAT
TTGCCTTAAACAAGACCACGAAA
Pax6-
CGGAGTGAATCA GCTCGGTG
CCGCTTATACTGGGCTATTTTGC
TUJ
GCGAGATGTACGAAGACGAC
TTTAGACACTGCTGGCTTCG
LMX1A
AGGAAGGCAA GGACCATAAGC
ATGCTCGCCTCTGTTGAGTTG
Gene expression analysis
Total RNA was isolated on day 30 using RNeasy mini kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. cDNA was synthesized using PrimeScript
RT Master Mix (TaKaRa, Lexington, MA, USA). Quantitative real-time PCR (qPCR) was
preformed using iQSYBR mix (BioRad, USA) according to the manufacturer’s protocol
and using specific forward and reverse primers listed in Table 2. qPCR results were analyzed
using the 1 1CT relative quantification method.
Immunofluorescence staining of neuronal markers
After 7 and 30 days of induction, cells on coverslips were fixed in 4% formaldehyde
for 15 min and permeablized with 1X PBS containing 0.1% TritonX-100 for 5 min. To
prevent nonspecific binding, cells were incubated with blocking solution consisting of
10% normal goat serum and 0.3% TritonX-100 (v/v) in 1X PBS for 60 min. Cells were
then incubated with the primary antibodies against SOX2, SOX1, TUJ1, Nestin, PAX6,
and TH diluted in blocking buffer overnight at 4 ◦ C. Subsequently cells were incubated
with appropriate secondary antibodies at 4 ◦ C in the dark and then DAPI staining and
mounting onto microscope slides. Cells were imaged using AxioObserever Z1 microscope
(Zeiss, Germany).
Statistical analysis
All the experiments were done at least three times and statistical analysis was performed
using GraphPad Prism (Version 6). The data were presented as the mean ± standard
error of the mean (SEM). Statistical differences were calculated using One-Way Analysis of
Variance (ANOVA 1) and Post-hoc test for comparison between groups. Differences were
considered significant at (* P < 0.05, ** P < 0.01, *** P < 0.001).
RESULTS
Isolation and characterization of ADSCs
On the third day of primary culture, cells with fibroblastic morphology were adhered to the
tissue culture plate and became confluent within 14 days of initial plating. To validate the
stemness of the isolated cells, MSCs from different sources were transdifferentiated into
the adipogenic and osteogenic cell lineages. Cells induced with adipogenic media for 14
days exhibited intracellularly localized lipid droplets stained with Oil red O (ORO), which
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
5/18
were absent in the negative control (Fig. 1A). Following 14 days of osteogenic induction,
cells exhibited flattened and more elongated morphology with extracellular deposits. The
presence of extracellular calcium phosphate deposits was confirmed with Alizarin Red
stain (ARS), which were absent in the uninduced negative controls (Fig. 1B). Thus, the
cells were successfully differentiated into osteoblasts and pre-adipocytes, confirming the
multi-potency of these cells. Flow cytometry analysis showed positive expression of the
following MSCs markers: CD-90, CD-105, CD-73 and minimal to no expression of markers
in the negative cocktail (Fig. 2A).
Analysis of cellular proliferation
Cellular proliferation was assessed using MTT assay to compare the proliferation rate
between MSCs-derived from AT, BM and WJ. After 48 h, no significant difference in the
proliferation rate was observed between the analyzed cell types. However, WJ derived MSCs
showed a significantly higher proliferation after 72 h compared to BM and AT-derived
MSCs (P = 0.009) (Fig. 2B).
Morphological analysis of MSCs induced towards the neuronal
lineage
The morphology of MSCs induced towards the dopaminergic lineage demonstrated
several alterations throughout the differentiation process. Initially, the three different MSC
types-derived from AT, BM and WJ adhered to the culture flask and exhibited a spindleshaped morphology. Following splitting and prolonged culture, cells began to change in
shape and acquire a more spherical appearance, obtaining a neural-like morphology with
the appearance of cellular processes (Fig. 3A). This change was more distinguishable in
WJ-MSC compared to AT-MSC and BM-MSCs.
Molecular analysis of neuronal induction
Quantitative real-time PCR was used to evaluate the relative expression of the following
neuronal genes: β Tubulin III (TUJ1), Nestin, NKX6.1, SOX2, PAX6 and LMX at the
transcriptional levels. Expression levels of the same target genes in undifferentiated original
MSCs were considered as the baseline level. The expression of TUJ1 gene, a neuronal marker
of immature neurons, was upregulated in all differentiated MSCs without any significant
differences between different MSC sources (Fig. 3B). Nestin gene expression, a marker of
neural progenitors, revealed a significant upregulation in WJ compared to AT (*P < 0.05)
and BM (**P < 0.01) derived MSCs ((Fig. 3B). On the other hand, NKX6.1 is also an early
neuronal progenitor marker, was upregulated without any statistical differences between
the induced MSC types. SOX2 is a marker for early and intermediate progenitor neuronal
cells (Fig. 3B). Levels of expression of this gene in WJ derived MSCs was significantly higher
compared to BM derived cells (*P < 0.05). Additionally, PAX6 an intermediate progenitor
marker was significantly upregulated in WJ derived MSCs compared to AT and BM
derived MSCs (****P < 0.0001). Additionally, we analyzed the expression of LMX1a (LIM
homeobox transcription factor 1, alpha) gene associated with the differentiation towards
dopaminergic neurons, and we found that WJ derived MSCs expressed significantly higher
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
6/18
BM
AT
WJ
BM
AT
WJ
Adipogenic
Differentiation
Control
A)
Osteogenic
Differentiation
Control
B)
Figure 1 Characterization of MSCs by multilineage differentiation analysis. (A) BM, AT and WJ tissue derived MSCs after 14 days of adipogenic differentiation, showing internal lipid droplets following
staining with Oil Red O, which were absent in the undifferentiated controls. (B) MSCs after 14 days of osteogenic differentiation, showing mineral deposition after staining with Alizarin Red stain (ARS), which
were absent in the undifferentiated controls.
Full-size DOI: 10.7717/peerj.13003/fig-1
levels compared to BM and AT derived MSCs (**P < 0.01), which suggests that our
protocol could direct this types of MSCs towards a dopaminergic-like phenotype (Fig. 3B).
Gene expression results support the morphological changes seen under the microscope
and support the idea that our differentiation protocol successfully generated neural
stem/progenitor-like cells from MSCs derived from BM, AT and WJ.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
7/18
A)
CD105
CD73
Negative cocktail
WJ
AT
BM
CD90
B)
MTT 24h
MTT 48h
0.6
Absorbance
Absorbance
0.8
0.4
0.2
1.0
0.8
0.8
0.6
0.4
0.2
0.0
BM
WJ
✱
0.6
0.4
0.2
0.0
AT
MTT 72
1.0
Absorbance
1.0
0.0
AT
BM
WJ
AT
BM
WJ
Figure 2 Characterization of MSCs by flow cytometry and comparison of proliferation potential. (A)
Flow cytometry analysis of MSCs showed that cells were positive for MSC markers CD-90, CD-105, CD73 and negative for the negative cocktail mix. N = 18 (B) Proliferation analysis of MSCs from BM, AT and
WJ samples. MTT assay was performed on cells cultured for 24, 48 and 72 h. N = 18 , * P < 0.05.
Full-size DOI: 10.7717/peerj.13003/fig-2
Assessment of neuronal induction by immunofluorescence
Since the morphological and gene expression results revealed a successful differentiation
into the neuronal-like lineage, we confirmed the expression of NESTIN, TUJ1, SOX1, SOX2
and PAX6 by immunofluorescent staining. All of these early neuronal progenitor markers
were expressed in all type of induced MSCs (Figs. 4 & 5). However, a more prominent
expression of these markers in WJ-derived MSCs was detected compared to AT and BM
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
8/18
A)
Day 30
BM
Day 30
AT
Day 30
WJ
B)
c)
Nestin
Relative Gene Expression
4
3
2
1
0
4
2
0
BM
AT
40
20
0
BM
WJ
AT
6
4
2
0
BM
AT
8
6
4
2
0
BM
✱✱✱✱
8
NKX6.1
WJ
PAX6
e)
✱
6
60
WJ
SOX2
d)
✱
Relative Gene Expression
AT
80
Relative Gene Expression
✱✱
5
BM
Relative Gene Expression
b)
TUJ1
Relative Gene Expression
Relative Gene Expression
a)
WJ
AT
f)
LMX
80
✱✱
WJ
60
40
20
0
BM
AT
WJ
Figure 3 Induction of MSCs into neural stem cell-like cells utilizing dual SMAD inhibition. (A) Phasecontrast images of BM, AT and WJ MSCs, respectively, showing the morphological changes after 30 days
in culture. Scale bar: 100 µm. (B) Quantitative real-time PCR was used to assess the expression of TUJ1,
Nestin, NKX6.1, SOX2, PAX6 and LMX genes on cultured neurons. Relative gene expression of each gene
was normalized to the expression of GAPDH housekeeping gene. Data represents means ± SEM of three
independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.
Full-size DOI: 10.7717/peerj.13003/fig-3
derived MSCs. Additionally, cells were stained for TH (Tyrosine Hydroxylase) and FOXA-2
(Forkhead box protein A2) as markers for differentiation towards the dopaminergic lineage.
WJ-MSCs showed higher expression levels compared to the other sourdes, which might
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
9/18
A)
B)
Nestin
DAPI
Merge
Day 7
BM
AT
WJ
BM
SOX2
40
20
WJ
AT
% SOX2/Nestin
60
SO
X2
es
tin
N
SO
X2
es
tin
N
N
SO
X2
es
tin
0
Day 7
C)
D)
DAPI
Merge Day 7
BM
AT
WJ
20
0
SO
X1
Tu
j1
% SOX1/Tuj1
40
SO
X1
Tu
j1
WJ
AT
60
SO
X1
Tu
j1
Tuj1
BM
SOX1
Day 7
Figure 4 Immunofluorescence analysis of neuronal markers at day 7. Neural stem cells differentiated
from MSCs and cultured in neuronal induction media were analyzed by immunofluorescence staining
on day 7 for the expression of neural stem/progenitor protein markers (A) SOX2 and Nestin. Scale bar =
50 µm. (B) Semi-quantitative analysis of SOX2 and Nestin representing the percent of positive cells. (C)
SOX1 and TUJ1, Scale bar = 50 µm (D) Semi-quantitative analysis of SOX1 and TUJ1 immunofluorescence representing the percent of positive cells. All experiments were repeated at least three independent
times.
Full-size DOI: 10.7717/peerj.13003/fig-4
suggest that WJ represents a more efficient cell source for neuronal cell differentiation
(Fig. 6).
DISCUSSION
The regeneration of neurons following injury is minimal and neurogenesis is limited
to specific parts of the brain (Hess & Borlongan, 2008). Several clinical trials have been
conducted using MSCs from different sources to establish their safety and efficacy for the
treatment of many neurological disorders such as Parkinson’s disease, multiple sclerosis
and amyotrophic lateral sclerosis (Boroujeni & Gardaneh, 2017; Karussis et al., 2010; Syková
et al., 2017). In vitro differentiation studies utilizing MSCs isolated from different tissues
have shown variable proliferation and differentiation potential (Alizadeh et al., 2019;
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
10/18
A)
Nestin
DAPI
B)
Merge Day 30
BM
SOX2
BM
AT
WJ
AT
% SOX2/Nestin
60
40
20
SO
X
N 2
es
tin
SO
X
N 2
es
tin
SO
X
N 2
es
tin
WJ
0
Day 30
C)
Tuj1
DAPI
Merge Day 30
D)
BM
AT
WJ
BM
SOX1
20
SO
X1
Tu
j1
0
SO
X1
Tu
j1
% SOX1/Tuj1
40
SO
X1
Tu
j1
WJ
AT
60
Day 30
Figure 5 Immunofluorescence analysis of neuronal markers at day 30. MSCs derived from bone marrow, adipose and Wharton’s jelly tissue cultured in neuron induction media were analyzed on day 30 for
the expression of neural stem/progenitor protein markers (A) SOX2 and Nestin. Scale bar = 50 mm. (B)
Semi-quantitative analysis of SOX2 and Nestin immunofluorescence representing percentage of positive
cells relative to negative control. (C) SOX1 and TUJ1, Scale bar = 50 mm (D) Semi-quantitative analysis
of SOX2 and Nestin immunofluorescence representing percentage of positive cells. All experiments were
repeated at least three times.
Full-size DOI: 10.7717/peerj.13003/fig-5
Balasubramanian et al., 2013; Datta et al., 2011; Urrutia et al., 2019). These variabilities can
significantly impact the clinical outcome. Accordingly, there is a need to provide a clear
overview and comparison on the neuronal differentiation potential of MSCs isolated from
different sources. Thus, the aim of this study was to provide a comparative view of the
capabilities of MSCs isolated from different human tissue sources, to differentiate into
neuronal stem cell-like cells and dopaminergic-like cells. The data described here shed
the light on the most appropriate MSC source of to be used therapeutically in neural
regenerative therapies.
Here we confirm that MSCs isolated from adipose tissue, bone marrow, and Wharton’s
jelly express similar surface markers and they are capable of undergoing multilineage
differentiation. The proliferative capacity of MSCs appear to be similar across the three
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
11/18
A)
FOXA2
Merge Day 30
DAPI
WJ
AT
BM
TH
BM
AT
WJ
B)
% FOXA2/TH
60
40
20
TH
2
FO
XA
TH
2
FO
XA
TH
FO
XA
2
0
Day 30
Figure 6 Immunofluorescence analysis of mature neuronal markers at day 30. The expression of
dopaminergic markers (A) FOXA2 and Tyrosine hydroxylase was analyzed by immunofluorescence
staining on cells cultured for 30 days in neuronal induction media. Scale bar = 50 mm. (B) Semiquantitative analysis of FOXA2 and TH immunofluorescence representing the percentage of positive cells.
All experiments were repeated at least three times.
Full-size DOI: 10.7717/peerj.13003/fig-6
different types of MSCs with minor variations. These variations can result from culture
heterogenicity, and different proportions of self-renewing cells in comparison to lineagespecific cells in different tissues. Previous studies have reported different proliferative
capabilities of MSCs. Urrutia et al. reported higher proliferation rate of AT compared to
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
12/18
WJ and BM-derived stem cells (Urrutia et al., 2019). On the other hand Hu et al. reported
results that contradict the above, in which WJ had higher proliferation rate compared to
AT (Hu et al., 2013). Other studies have also reported varying results (Aliborzi et al., 2016;
Heidari et al., 2013). Such variabilities might be attributed to differences in isolation and
culture methods or differences due to age, sex and health status of the samples donors.
The assay of choice used to measure the proliferation capacity plays a critical contribution
as well. Such results are of importance for the selection of an appropriate tissue source to
derive MSCs for the use in cell-based therapies, which are required in sufficient numbers
in a limited time to achieve effective clinical outcomes. Hence, further rigorous analysis
must be conducted to clearly identify differences in proliferation capacities, with matched
large samples, and utilizing unified consistent methods.
Studies in animal models as well as human cell lines have shown that bone morphogenetic
protein (BMP) and the Activin/Nodal pathway play a significant role in neural development
of embryos as well as neuronal differentiation of different types of stem cells (Park et al.,
2017; Wattanapanitch et al., 2014). Several differentiation studies have demonstrated the
synergistic inhibition of those two pathways utilizing a small molecules cocktail such as SB
431542, Noggin, LDN 193189 to induce the cells towards the neural progenitor fate that
can then be differentiated to a more mature neural cell type (Park et al., 2017; Pauly et al.,
2018; Wattanapanitch et al., 2014).
Here, we utilized a combination of small molecules to direct the differentiation of MSCs
towards the neural lineage in a serum-free environment. Small molecules are relatively
cheap, stable and have high penetrating capability. Briefly, we employed dual-SMAD
inhibition during the initial stage of differentiation. Dual SMAD inhibition was achieved
by adding SB-431542 as a TGF- β inhibitor and LDN-193189 as a BMP-inhibitor to
induce the neural lineage. Thus, revealed that MSCs from different sources are capable
of generating neural stem cell (NSC)-like cells. Following 7 days of the initial induction,
MSCs derived from different human tissue-sources changed their morphology into spindled
neuronal-like shape. Furthermore, we assessed the expression of a group of NSC markers,
including Nestin, Tuj1, Pax6, Sox1, Sox2. Our results point towards the ability of MSCs to
differentiate into neural stem cell-like phenotype. These cells are of interest to provide an
intermediate neural cell source that can be further differentiated into a more mature state.
However, it is important to note that these cells must be further characterized for their
purity and the ability to express a comprehensive panel of NSC markers. Furthermore,
the ability of these cells to expand with high efficiency in culture must be systematically
evaluated.
Several different studies have attempted to induce the differentiation of MSCs from
different sources towards dopaminergic neurons to assess their ability to be used in cell
based therapies for neurodegenerative diseases such as Parkinson’s disease (Adib et al., 2015;
Tatard et al., 2007; Trzaska, Kuzhikandathil & Rameshwar, 2007). A wide array of small
molecules, cytokines and neurotrophic factors, have been used in different differentiation
protocols. For instance, brain and glial derived neurotrophic factors, FGF-8, SHH, cAMP,
DAPT have been utilized frequently in neuronal induction (Adib et al., 2015; Tatard et al.,
2007; Trzaska, Kuzhikandathil & Rameshwar, 2007).
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
13/18
Here, we assessed the ability of the generated NSC-like cells to differentiate into
dopaminergic neurons. Quantitative Real-time PCR and immunostaining of some
dopaminergic-specific markers revealed the higher differentiation potential of WJ derived
cells towards the neural lineage compared to AT and BM derived MSCs. It is noteworthy
that the utilization of different differentiation protocols, sample pool, as well as different
analysis tools might lead to significant variation in the differentiation results. Accordingly,
a large-scale study with in depth analysis is required in order to verify the exact potential
of each MSCs type.
CONCLUSION
In this study, we report that MSCs derived from adipose tissue, bone marrow and
Wharton’s jelly can be induced to differentiate into neuron-like cells and further matured
into dopaminergic-like phenotype. WJ-MSCs showed a higher neuronal differentiation
potential compared to AT and BM derived MSCs. The differentiation of MSCs into neural
cells might be a realistic goal as evident by the expression of some neuronal markers after
cellular induction. However, it is still early to claim that these generated neuronal cells can be
used in cell-based therapies, especially that such differentiation protocols dictate that these
cells must cross mesodermal lineage towards a neuroectodermal lineage. The efficiency of
all trans-differentiation protocols is still debatable and must be comprehensively analyzed
in vivo to confirm the terminal differentiation potential.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
This work was supported by the deanship of scientific research University of Jordan Grant
No. 2000. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Grant Disclosures
The following grant information was disclosed by the authors:
Scientific research University of Jordan: 2000.
Competing Interests
The authors declare there are no competing interests.
Author Contributions
• Nidaa A. Ababneh and Ban Al-Kurdi conceived and designed the experiments, performed
the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed
drafts of the paper, and approved the final draft.
• Fatima Jamali and Abdalla Awidi conceived and designed the experiments, authored or
reviewed drafts of the paper, and approved the final draft.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
14/18
Ethics
The following information was supplied relating to ethical approvals (i.e., approving body
and any reference numbers):
an International Review Board (IRB/7/2019) approval at the University of Jordan/Cell
Therapy Center (CTC).
Data Availability
The following information was supplied regarding data availability:
The gene expression analysis data is available in the Supplemental Files.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/
peerj.13003#supplemental-information.
REFERENCES
Adib S, Tiraihi T, Darvishi M, Taheri T, Kazemi H. 2015. Cholinergic differentiation
of neural stem cells generated from cell aggregates-derived from Human Bone
marrow stromal cells. Tissue Engineering and Regenerative Medicine 12(1):43–52
DOI 10.1007/s13770-014-0019-6.
Alexander GE. 2004. Biology of Parkinson’s disease: pathogenesis and pathophysiology
of a multisystem neurodegenerative disorder. Dialogues in Clinical Neuroscience
6(3):259–280 DOI 10.31887/DCNS.2004.6.3/galexander.
Aliborzi G, Vahdati A, Mehrabani D, Hosseini SE, Tamadon A. 2016. Isolation,
characterization and growth kinetic comparison of bone marrow and adipose
tissue mesenchymal stem cells of guinea pig. International Journal of Stem Cells
9(1):115–123 DOI 10.15283/ijsc.2016.9.1.115.
Alizadeh R, Bagher Z, Kamrava SK, Falah M, Ghasemi Hamidabadi H, Eskandarian Boroujeni M, Mohammadi F, Khodaverdi S, Zare-Sadeghi A, Olya A,
Komeili A. 2019. Differentiation of human mesenchymal stem cells (MSC) to
dopaminergic neurons: a comparison between Wharton’s jelly and olfactory
mucosa as sources of MSCs. Journal of Chemical Neuroanatomy 96:126–133
DOI 10.1016/j.jchemneu.2019.01.003.
Balasubramanian S, Thej C, Venugopal P, Priya N, Zakaria Z, Sundarraj S, Majumdar
A. Sen. 2013. Higher propensity of Wharton’s jelly derived mesenchymal stromal
cells towards neuronal lineage in comparison to those derived from adipose and
bone marrow. Cell Biology International 37(5):507–515 DOI 10.1002/cbin.10056.
Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D. 2009. Lentiviral delivery
of LMX1a enhances dopaminergic phenotype in differentiated human bone
marrow mesenchymal stem cells. Stem Cells and Development 18(4):591–601
DOI 10.1089/scd.2008.0138.
Boroujeni ME, Gardaneh M. 2017. Umbilical cord: an unlimited source of cells
differentiable towards dopaminergic neurons. Neural Regeneration Research
12(7):1186–1192 DOI 10.4103/1673-5374.211201.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
15/18
Boroujeni ME, Gardaneh M, Shahriari MH, Aliaghaei A, Hasani S. 2017. Synergy
between choroid plexus epithelial cell-conditioned medium and knockout serum
replacement converts human adipose-derived stem cells to dopamine-secreting
neurons. Rejuvenation Research 20(4):309–319 DOI 10.1089/rej.2016.1887.
Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. 2008. Adipose-derived stem cells:
isolation, expansion and differentiation. Methods 45(2):115–120
DOI 10.1016/j.ymeth.2008.03.006.
Datta I, Mishra S, Mohanty L, Pulikkot S, Joshi PG. 2011. Neuronal plasticity of human
Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared
with human bone marrow mesenchymal stromal cells. Cytotherapy 13(8):918–932
DOI 10.3109/14653249.2011.579957.
Dauer W, Przedborski S. 2003. Parkinson’s disease: mechanisms and models. Neuron
39(6):889–909 DOI 10.1016/s0896-6273(03)00568-3.
Fu M-H, Li C-L, Lin H-L, Chen P-C, Calkins MJ, Chang Y-F, PC SY. 2015. Stem cell
transplantation therapy in Parkinson’s disease. SpringerPlus 4:597
DOI 10.1186/s40064-015-1400-1.
Gnecchi M, Melo LG. 2009. Bone marrow-derived mesenchymal stem cells: isolation,
expansion, characterization, viral transduction, and production of conditioned
medium. Methods in Molecular Biology 482:281–294
DOI 10.1007/978-1-59745-060-7_18.
Heidari B, Shirazi A, Akhondi MM, Hassanpour H, Behzadi B, Naderi MM, Sarvari
A, Borjian S. 2013. Comparison of proliferative and multilineage differentiation
potential of sheep mesenchymal stem cells derived from bone marrow, liver, and
adipose tissue. Avicenna Journal of Medical Biotechnology 5(2):104–117.
Hess DC, Borlongan CV. 2008. Stem cells and neurological diseases. Cell Proliferation
41(Suppl 1):94–114 DOI 10.1111/j.1365-2184.2008.00486.x.
Hu L, Hu J, Zhao J, Liu J, Ouyang W, Yang C, Gong N, Du L, Khanal A, Chen L. 2013.
Side-by-side comparison of the biological characteristics of human umbilical cord
and adipose tissue-derived mesenchymal stem cells. BioMed Research International
2013:438243 DOI 10.1155/2013/438243.
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM,
Kassis I, Bulte JWM, Petrou P, Ben-Hur T, Abramsky O, Slavin S. 2010. Safety
and immunological effects of mesenchymal stem cell transplantation in patients
with multiple sclerosis and amyotrophic lateral sclerosis. Archives of Neurology
67(10):1187–1194 DOI 10.1001/archneurol.2010.248.
Khademizadeh M, Messripour M, Ghasemi N, Momen Beik F, Movahedian Attar A, Kim TE, Lee HS, Lee YSYB, Hong SH, Lee YSYB, Ichinose H, Kim SU,
Lee MA. 2019. Differentiation of adult human mesenchymal stem cells into
dopaminergic neurons. Research in Pharmaceutical Sciences 14(3):209–215
DOI 10.4103/1735-5362.258487.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
16/18
Marei HES, El-Gamal A, Althani A, Afifi N, Abd-Elmaksoud A, Farag A, Cenciarelli C,
Thomas C, Anwarul H. 2018. Cholinergic and dopaminergic neuronal differentiation of human adipose tissue derived mesenchymal stem cells. Journal of Cellular
Physiology 233(2):936–945 DOI 10.1002/jcp.25937.
Medvedev SP, Shevchenko AI, Zakian SM. 2010. Induced pluripotent stem cells:
problems and advantages when applying them in regenerative medicine. Acta
Naturae 2(2):18–28 DOI 10.32607/20758251-2010-2-2-18-27.
Musiał-Wysocka A, Kot M, Majka M. 2019. The pros and cons of mesenchymal stem
cell-based therapies. Cell Transplantation 28(7):801–812
DOI 10.1177/0963689719837897.
Orbay H, Tobita M, Mizuno H. 2012. Mesenchymal stem cells isolated from adipose
and other tissues: basic biological properties and clinical applications. Stem Cells
International 2012:461718 DOI 10.1155/2012/461718.
Park J, Lee N, Lee J, Choe EK, Kim MK, Lee J, Byun MS, Chon M-W, Kim SW, Lee CJ,
Kim JH, Kwon JS, Chang M-S. 2017. Small molecule-based lineage switch of human
adipose-derived stem cells into neural stem cells and functional GABAergic neurons.
Scientific Reports 7(1):10166 DOI 10.1038/s41598-017-10394-y.
Pauly MG, Krajka V, Stengel F, Seibler P, Klein C, Capetian P. 2018. Adherent vs. Freefloating neural induction by dual smad inhibition for neurosphere cultures derived
from human induced pluripotent stem cells. Frontiers in Cell and Developmental
Biology 6:3 DOI 10.3389/fcell.2018.00003.
Ranjbaran H, Abediankenari S, Mohammadi M, Jafari N, Khalilian A, Rahmani Z,
Momeninezhad Amiri M, Ebrahimi P. 2018. Wharton’s jelly derived-mesenchymal
stem cells: isolation and characterization. Acta Medica Iranica 56(1):28–33.
Syková E, Rychmach P, Drahorádová I, Konrádová Š, Růžičková K, Voříšek I,
Forostyak S, Homola A, Bojar M. 2017. Transplantation of mesenchymal stromal
cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial.
Cell Transplantation 26(4):647–658 DOI 10.3727/096368916X693716.
Tatard VM, D’Ippolito G, Diabira S, Valeyev A, Hackman J, McCarthy M, Bouckenooghe
T, Menei P, Montero-Menei CN, Schiller PC. 2007. Neurotrophin-directed
differentiation of human adult marrow stromal cells to dopaminergic-like neurons.
Bone 40(2):360–373 DOI 10.1016/j.bone.2006.09.013.
Trzaska KA, Kuzhikandathil EV, Rameshwar P. 2007. Specification of a dopaminergic
phenotype from adult human mesenchymal stem cells. Stem Cells (Dayton, Ohio)
25(11):2797–2808 DOI 10.1634/stemcells.2007-0212.
Ul Hassan A, Hassan G, Rasool Z. 2009. Role of stem cells in treatment of neurological
disorder. International Journal of Health Sciences 3(2):227–233.
Ullah I, Subbarao RB, Rho GJ. 2015. Human mesenchymal stem cells—current trends
and future prospective. Bioscience Reports 35(2):e00191 DOI 10.1042/BSR20150025.
Urrutia DN, Caviedes P, Mardones R, Minguell JJ, Vega-Letter AM, Jofre CM. 2019.
Comparative study of the neural differentiation capacity of mesenchymal stromal
cells from different tissue sources: an approach for their use in neural regeneration
therapies. PLOS ONE 14(3):e0213032 DOI 10.1371/journal.pone.0213032.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
17/18
Wang M, Yuan Q, Xie L. 2018. Mesenchymal stem cell-based immunomodulation:
properties and clinical application. Stem Cells International 2018:3057624
DOI 10.1155/2018/3057624.
Wattanapanitch M, Klincumhom N, Potirat P, Amornpisutt R, Lorthongpanich
C, U-pratya Y, Laowtammathron C, Kheolamai P, Poungvarin N, Issaragrisil
S. 2014. Dual small-molecule targeting of SMAD signaling stimulates human
induced pluripotent stem cells toward neural lineages. PLOS ONE 9(9):e106952
DOI 10.1371/journal.pone.0106952.
Yang W-H, Yang C, Xue Y-Q, Lu T, Reiser J, Zhao L-R, Duan W-M. 2013. Regulated
expression of lentivirus-mediated GDNF in human bone marrow-derived mesenchymal stem cells and its neuroprotection on dopaminergic cells in vitro. PLOS ONE
8(5):e64389–e64389 DOI 10.1371/journal.pone.0064389.
Ababneh et al. (2022), PeerJ, DOI 10.7717/peerj.13003
18/18